Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation (HSCT) to Reduce the Risk of Infection and Graft vs. Host Disease (GvHD)

Next Previous
Trial Profile

A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of SER-155 in Adults Undergoing Hematopoietic Stem Cell Transplantation (HSCT) to Reduce the Risk of Infection and Graft vs. Host Disease (GvHD)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SER-155 (Primary) ; Vancomycin
  • Indications Bacteraemia; Graft-versus-host disease; Intra-abdominal infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Seres Therapeutics

Most Recent Events

  • 27 May 2025 Results presented in a Seres Therapeutics media release.
  • 29 Apr 2025 According to a Seres Therapeutics media release, data from this trial will be presented at the upcoming 2025 Digestive Disease Week (DDW) Conference being held May 3-6, 2025, in San Diego, CA.
  • 13 Mar 2025 According to a Seres Therapeutics media release, company Present SER-155 Phase 1b clinical and exploratory translational biomarker data as a Top 100 abstract at the European Bone Marrow Transplant meeting in March 2025, Additionally, exploratory translational biomarker data from across Seres' programs, including in allo0-HSCT and IBD, have been accepted for poster presentations at Digestive Disease Week (DDW) in May 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top